Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus.
Brüggen MC, Le ST, Walsh S, Toussi A, de Prost N, Ranki A, Didona B, Colin A, Horváth B, Brezinova E, Milpied B, Moss C, Bodemer C, Meyersburg D, Salavastru C, Tiplica GS, Howard E, Bequignon E, Bouwes Bavinck JN, Newman J, Gueudry J, Nägeli M, Zaghbib K, Pallesen K, Bygum A, Joly P, Wolkenstein P, Chua SL, Le Floch R, Shear NH, Chu CY, Hama N, Abe R, Chung WH, Shiohara T, Ardern-Jones M, Romanelli P, Phillips EJ, Stern RS, Cotliar J, Micheletti RG, Brassard A, Schulz JT, Dodiuk-Gad RP, Dominguez AR, Paller AS, Seminario-Vidal L, Mostaghimi A, Noe MH, Worswick S, Tartar D, Sheridan R, Kaffenberger BH, Shinkai K, Maverakis E, French LE, Ingen-Housz-Oro S. Brüggen MC, et al. Among authors: milpied b. Br J Dermatol. 2021 Sep;185(3):616-626. doi: 10.1111/bjd.19893. Epub 2021 Apr 27. Br J Dermatol. 2021. PMID: 33657677
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Wolkenstein P, et al. Among authors: milpied b. Lancet. 1998 Nov 14;352(9140):1586-9. doi: 10.1016/S0140-6736(98)02197-7. Lancet. 1998. PMID: 9843104 Clinical Trial.
A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J; Toxidermies group of the French Society of Dermatology. Barbaud A, et al. Among authors: milpied b. Br J Dermatol. 2013 Mar;168(3):555-62. doi: 10.1111/bjd.12125. Br J Dermatol. 2013. PMID: 23136927
Severe cutaneous adverse reactions due to inappropriate medication use.
Chaby G, Valeyrie-Allanore L, Duong TA, Lebrun-Vignes B, Milpied B, Sassolas B, Tetart F, Wolkenstein P, Chosidow O, Fardet L. Chaby G, et al. Among authors: milpied b. Br J Dermatol. 2018 Aug;179(2):329-336. doi: 10.1111/bjd.16365. Epub 2018 May 14. Br J Dermatol. 2018. PMID: 29352771
A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices.
Kechichian E, Ingen-Housz-Oro S, Sbidian E, Hemery F, Bernier C, Fite C, Delaunay J, Staumont-Sallé D, Toukal F, Dupin N, Abasq C, Samimi M, Picard C, Hebert V, Prost C, Monfort JB, Milpied B, Wolkenstein P, Chosidow O. Kechichian E, et al. Among authors: milpied b. Br J Dermatol. 2018 Oct;179(4):1009-1011. doi: 10.1111/bjd.16928. Epub 2018 Aug 16. Br J Dermatol. 2018. PMID: 29957881 No abstract available.
162 results